The European Association of Urology (EAU) stands as the foremost authority in Europe on urological practice, research, and education. With over 19,000 members, the EAU has made significant contributions to enhancing urological care across Europe and globally. Since its inception in the early 1970s, the association has expanded its influence and scope, playing a vital role in shaping urological standards. Its primary goal is to develop evidence-based clinical guidelines that not only support urologists in clinical decision-making but also empower patients in their care through shared decision-making. This focus aligns with the growing emphasis on personalized, patient-centered approaches in urology.

On March 20, 2025, the EAU released five updated guidelines addressing the following areas: Male Sexual and Reproductive Health, Upper Urinary Tract Urothelial Carcinoma, Paediatric Urology, Renal Cell Carcinoma, and Muscle-invasive and Metastatic Bladder Cancer. In this Guidelines Spotlight, we will review the key takeaways from each of these revised guidelines.

Guidelines and Key Takeaways

Male Sexual and Reproductive Health 

Key Takeaways:

  • Comprehensive Male Fertility Evaluation: The guideline stresses the importance of thorough evaluation of male fertility, which includes clinical assessment, semen analysis, hormonal tests, and imaging studies to diagnose underlying conditions contributing to male infertility.
  • Medical Management of Male Infertility: Evidence-based medical therapies such as clomiphene citrate, aromatase inhibitors, and gonadotropins are discussed for managing male infertility due to hypogonadism or other endocrine disturbances.
  • Testicular Sperm Extraction (TESE): Recommendations are provided for utilizing TESE in non-obstructive azoospermia, with emphasis on selecting candidates who would benefit from the procedure.
  • Management of Erectile Dysfunction (ED): The guidelines address both pharmacologic (PDE5 inhibitors, vacuum erection devices) and nonpharmacologic treatments (psychological counseling, lifestyle changes) to manage ED effectively, emphasizing a multimodal approach.
  • Impact of Obesity on Male Sexual Health: There is a focus on the association between obesity, testosterone deficiency, and sexual dysfunction, with recommendations for weight management as part of a comprehensive treatment plan.

Upper Urinary Tract Urothelial Carcinoma 

Key Takeaways:

  • Early Diagnosis and Risk Stratification: The guideline underscores the importance of early detection, including advanced imaging techniques such as CT urography and MRI, along with urine biomarkers to improve diagnostic accuracy and determine the extent of disease.
  • Nephron-Sparing Surgery: Recommendations are provided for nephron-sparing surgeries, such as partial nephrectomy or endoscopic resection, especially in low-risk patients to preserve renal function.
  • Role of Chemotherapy and Immunotherapy: Chemotherapy remains the first-line systemic treatment for metastatic upper urinary tract urothelial carcinoma (UTUC), but emerging immune checkpoint inhibitors (e.g., pembrolizumab, atezolizumab) offer promising results for patients with advanced or metastatic disease.
  • Adjuvant Therapies: The guidelines suggest consideration of adjuvant chemotherapy in high-risk patients post-surgery, with a specific focus on improving survival outcomes in muscle-invasive disease.
  • Multidisciplinary Care: Collaborative management involving urologists, oncologists, and pathologists is essential for optimizing treatment strategies for UTUC.

Paediatric Urology 

Key Takeaways:

  • Congenital Disorders Management: The guideline highlights the management of congenital conditions such as hypospadias, undescended testes, and renal anomalies, with recommendations for early intervention to prevent long-term complications.
  • Urinary Tract Infections (UTIs) in Children: Emphasis is placed on the prompt diagnosis and treatment of UTIs, with attention to differentiating between simple and complex UTIs in pediatric patients. The guideline advocates for imaging in children with recurrent infections to rule out structural abnormalities.
  • Enuresis and Vesicoureteral Reflux (VUR): The treatment of nocturnal enuresis (bedwetting) includes behavior modification, medication (e.g., desmopressin), and in some cases, surgical intervention for VUR if it is severe or resistant to conservative management.
  • Renal Failure Management: The guideline recommends appropriate referral for renal transplantation or dialysis in cases of end-stage renal failure in children. This is particularly relevant for pediatric patients with chronic kidney disease due to urological disorders.
  • Minimally Invasive Techniques: A growing emphasis on laparoscopic and robotic-assisted surgeries for pediatric urological conditions to minimize morbidity and improve recovery times.

Renal Cell Carcinoma 

Key Takeaways:

  • Imaging and Diagnosis: Updated recommendations on the use of high-resolution imaging (CT, MRI) to detect renal cell carcinoma (RCC), with specific attention to distinguishing between benign and malignant renal masses.
  • Surgical Management: Partial nephrectomy is recommended for localized RCC whenever feasible to preserve renal function. Radical nephrectomy is still indicated for larger tumors or those with extensive involvement of the renal vasculature.
  • Systemic Therapy: Targeted therapies, including tyrosine kinase inhibitors (TKIs) such as sunitinib and pazopanib, along with immune checkpoint inhibitors (e.g., nivolumab), are recommended for advanced RCC. The combination of these therapies has shown improved progression-free survival.
  • Risk Stratification: Physicians are encouraged to utilize tools such as the MSKCC and IMDC scoring systems to assess prognosis and tailor systemic therapy based on risk stratification.
  • Follow-up Protocols: There is an emphasis on regular follow-up using imaging studies to detect recurrences, especially within the first 5 years after initial treatment, as RCC has a propensity to recur late.

Muscle-invasive and Metastatic Bladder Cancer 

Key Takeaways:

  • Diagnosis and Staging: The guideline stresses the importance of accurate staging using CT, MRI, and cystoscopy with biopsy, as staging directly influences treatment decisions. The addition of FDG-PET scans for detecting metastatic disease is also discussed.
  • Neoadjuvant Chemotherapy: Neoadjuvant chemotherapy (e.g., cisplatin-based regimens) is strongly recommended for muscle-invasive bladder cancer (MIBC) prior to radical cystectomy to improve survival outcomes.
  • Radical Cystectomy and Reconstruction: Radical cystectomy with pelvic lymph node dissection remains the gold standard for treatment of MIBC. Post-surgery, the choice of urinary diversion (ileal conduit, neobladder, or continent diversion) should be personalized based on patient factors.
  • Immunotherapy and Targeted Therapies: For metastatic bladder cancer, immune checkpoint inhibitors (e.g., pembrolizumab, atezolizumab) have revolutionized treatment, especially in patients who are not candidates for cisplatin-based chemotherapy. Targeted therapies are being explored in clinical trials.
  • Palliative Care: Emphasis on integrating palliative care early in metastatic bladder cancer, focusing on symptom management, improving quality of life, and supporting patient decision-making in advanced stages.

In conclusion, the European Association of Urology (EAU) continues to provide updated, evidence-based guidelines that tackle some of the most challenging areas in urology. The release of these five revised guidelines offers valuable insights for urologists seeking to optimize patient care. These updates reflect the latest clinical evidence, advances in diagnostic techniques, treatment options, and patient management strategies. For US physicians, these international recommendations offer a unique perspective on enhancing the quality of care, improving patient outcomes, and staying at the cutting edge of urological practice.

We hope you found this Guideline Spotlight informative. We look forward to hearing your thoughts and feedback as we continue to share valuable insights in our future spotlights. Thank you for being a valued member of our community!

Sign up for alerts and stay informed on the latest published guidelines and articles.

Copyright © 2025 Guideline Central, all rights reserved.